交易中 09-16 16:07:35 美东时间
-0.760
-6.56%
BioAge和Bicara希望扭转近期生物科技公司美股IPO遇阻的趋势;药物开发的二元性使得一些投资者远离生物科技行业。
09-05 15:08
Cantor Fitzgerald analyst Eric Schmidt reiterates Alumis (NASDAQ:ALMS) with a Overweight.
08-19 23:08
Alumis press release (NASDAQ:ALMS): Q2 As of June 30, 2024, Alumis had cash and cash equivalents and marketable securities of $209.5 million, which, together with aggregate net proceeds from the closi...
08-15 01:59
Leerink Partners analyst Thomas Smith has reiterated their bullish stance on AL...
08-01 14:26
Morgan Stanley analyst Terence Flynn initiates coverage on Alumis (NASDAQ:ALMS) with a Overweight rating and announces Price Target of $36.
07-23 17:44
雷递网雷建平7月7日 生物医药公司Alumis(NASDAQ:ALMS)日前在美国纳斯达克上市,发行价为16美元,发行1310万股。在首...
07-07 16:40
Clinical-stage biopharmaceutical company Alumis (NASDAQ:ALMS) is having a rough day on its first day of trading with shares trading well below its IPO price of $16/share. As of 130p ET, shares were tr...
06-29 01:37
Alumis priced its IPO at $16/share, raising $210 million with 13.13 million shares. Trading begins June 28, 2024. Alumis develops oral therapies for immune-mediated diseases, with its lead candidate ESK-001 targeting psoriasis and lupus.
06-29 01:36
生物制药公司Alumis(ALMS.US)拟以每股16.00美元的价格首次发行1312.5万股股票,将于今晚在纳斯达克交易。
06-28 21:24